Skip to main content

Table 5 Target therapy for mRCC

From: Surgical-only treatment of pancreatic and extra-pancreatic metastases from renal cell carcinoma - quality of life and survival analysis

TARGET THERAPY FOR mRCC – SCHEMES & RESULTS

Scheme/Drug

Line of Treatment

Molecular Target

Mean PFS (Months)

Mean OS(Months)

Sunitinib1,2

First

mTKI

11

26,4

Temsirolimus1

First

mTOR

1,9

10,9

Pazopanib1

First

mTKI

11,8

22,9

Sorafenib1

Second

mTKI

5,5

17,8

Bevacizumab + IFNα1

Second

VEGF-A

8,5

18,3

Axitinib1

Second

mTKI

6,7

20,1

Everolimus1

Second

mTOR

4

14,8

Nivolumab1

Second

PD-1

4,6

25

Cabozatinib1,2

Second

mTKI

7,4

21,4

Lenvatinb + Everolimus1

Second

mTKI/mTOR

14,6

NR

Nivolumab + Ipilimumab2

Second

PD-1/PD-L1

12,6

NR

Atezolizumab + Bevacizumab2

Second

PD-L1/VEGF-A

11,2

NR

  1. Legend: mTKI Multiple Tyrosine Kinase Inhibitor,VEGF-A Vascular Endotelial Growth Factor A, mTOR Mammalian Target of Rapamycin, PD-1 Programmed Death 1, PD-L1 Programmed Death Ligand 1, NR Not Reached